Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRB | P23467 | 7/20 | 0.57 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.39 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4009024 | 1.00 | PTPRB (0.57) | PTPRBPOLBLMNATSHRCSNK2A2 | |
| SCHEMBL686535 | 0.84 | MAPT (0.47) | PTPRBPOLBLMNAKDM4EALDH1A1 | |
| SCHEMBL23303560 | 0.78 | PTPRB (0.46) | PTPRBLMNAKDM4EALDH1A1NPC1 | |
| SCHEMBL8587434 | 0.78 | PTPRB (0.46) | PTPRBLMNAKDM4EALDH1A1NPC1 | |
| SCHEMBL3551815 | 0.76 | PTPRB (0.46) | PTPRBKDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL19945956 | 0.76 | PTPRB (0.46) | PTPRBKDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL29794284 | 0.76 | PTPRB (0.46) | PTPRBKDM4EALDH1A1NPC1RAB9A | |
| Ammonia Solution, Strong SCHEMBL19894166 | 0.75 | ADORA2A (0.35) | PTPRBPOLBLMNATSHRADORA3 | |
| SCHEMBL14303545 | 0.75 | PTPRB (0.56) | PTPRBPOLBLMNACSNK2A2CSNK2B | |
| SCHEMBL23303494 | 0.75 | PTPRB (0.59) | PTPRBKDM4ENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101506204-B | Human protein tyrosine phosphatase inhibitors and methods of use | WARNER CHILCOTT CO LLC | 2012-05-30 | — | — | CN | claimed |
| US-20120077853-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | EyePoint Pharmaceuticals, Inc. | 2012-03-29 | — | — | US | claimed |
| US-7589212-B2 | {4-[2-(5-methyl-[1,3,4]thiadiazol-2-ylamino)-2-(4-phenylthiazol-2-yl)-ethyl]phenyl}sulfamic acid; anticarcinogenic, antitumor, antidiabrtic agent; angiogenesis inhibitor; sarcoid, syphilis, Paget's disease, vein occlusion, artery occlusion, carotid obstructive disease, chronic uveitis/vitritis | PROCTER & GAMBLE COMPANY (US) | 2009-09-15 | — | — | US | claimed |
| US-20090227639-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | EyePoint Pharmaceuticals, Inc. | 2009-09-10 | — | — | US | claimed |
| CN-101506204-A | Human protein tyrosine phosphatase inhibitors and methods of use | PROCTER & GAMBLE (US) | 2009-08-12 | — | — | CN | claimed |
| US-20070299116-A1 | {4-[2-(5-methyl-[1,3,4]thiadiazol-2-ylamino)-2-(4-phenylthiazol-2-yl)-ethyl]phenyl}sulfamic acid; anticarcinogenic, antitumor, antidiabrtic agent; angiogenesis inhibitor; sarcoid, syphilis, Paget's disease, vein occlusion, artery occlusion, carotid obstructive disease, chronic uveitis/vitritis | THE PROCTER & GAMBLE COMPANY (US) | 2007-12-27 | — | — | US | claimed |
| EP-3287455-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | Aerpio Therapeutics, Inc. (US) | 2018-02-28 | — | — | EP | disclosed |
| EP-2803663-B1 | Human protein tyrosine phosphatase inhibitors and their pharmaceutical use | AERPIO THERAPEUTICS INC (US) | 2017-11-29 | — | — | EP | disclosed |
| EP-2803663-A1 | Human protein tyrosine phosphatase inhibitors and their pharmaceutical use | Aerpio Therapeutics Inc. (US) | 2014-11-19 | — | — | EP | disclosed |
| EP-2041129-B1 | Human protein-tyrosine phosphatase inhibitors and their pharmaceutical use | AERPIO THERAPEUTICS INC (US) | 2014-09-03 | — | — | EP | disclosed |
| CN-101506204-B | Human protein tyrosine phosphatase inhibitors and methods of use | WARNER CHILCOTT CO LLC | 2012-05-30 | — | — | CN | disclosed |
| US-8188125-B2 | Human protein tyrosine phosphatase inhibitors and methods of use | AERPIO THERAPEUTICS INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-7589212-B2 | {4-[2-(5-methyl-[1,3,4]thiadiazol-2-ylamino)-2-(4-phenylthiazol-2-yl)-ethyl]phenyl}sulfamic acid; anticarcinogenic, antitumor, antidiabrtic agent; angiogenesis inhibitor; sarcoid, syphilis, Paget's disease, vein occlusion, artery occlusion, carotid obstructive disease, chronic uveitis/vitritis | PROCTER & GAMBLE COMPANY (US) | 2009-09-15 | — | — | US | disclosed |
| US-20090227639-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | EyePoint Pharmaceuticals, Inc. | 2009-09-10 | — | — | US | disclosed |
| CN-101506204-A | Human protein tyrosine phosphatase inhibitors and methods of use | PROCTER & GAMBLE (US) | 2009-08-12 | — | — | CN | disclosed |
| US-20070299116-A1 | {4-[2-(5-methyl-[1,3,4]thiadiazol-2-ylamino)-2-(4-phenylthiazol-2-yl)-ethyl]phenyl}sulfamic acid; anticarcinogenic, antitumor, antidiabrtic agent; angiogenesis inhibitor; sarcoid, syphilis, Paget's disease, vein occlusion, artery occlusion, carotid obstructive disease, chronic uveitis/vitritis | THE PROCTER & GAMBLE COMPANY (US) | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299116-A1 | {4-[2-(5-methyl-[1,3,4]thiadiazol-2-ylamino)-2-(4-phenylthiazol-2-yl)-ethyl]phenyl}sulfamic acid; anticarcinogenic, antitumor, antidiabrtic agent; angiogenesis inhibitor; sarcoid, syphilis, Paget's disease, vein occlusion, artery occlusion, carotid obstructive disease, chronic uveitis/vitritis | DUSP15, PPP5C, DUSP1 | PTPRB 79/4885POLB 2268/4885LMNA 4409/4885 |
| US-20120077853-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | PTPRCAP, PPP5C, PTPRC | PTPRB 40/4885POLB 2156/4885LMNA 4555/4885 |
| US-20090227639-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | PTPRCAP, PPP5C, PTPRC | PTPRB 40/4885POLB 2156/4885LMNA 4555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.